A new medication will soon be available to heart failure patients, after a large study of the drug was stopped early in response to better-than-expected results.The medication is an angiotensin receptor-neprilysin inhibitor known as LCZ696 (Entresto). The U.S. Food and Drug Administration approved the drug earlier this summer. The drug helps widen arteries to improve blood flow, and, at the same time, helps lower the volume of fluid in the body. Last fall it was on Cleveland Clinics Top 10 Innovations for 2015-an annual list of medical breakthroughs expected in the coming year.
To continue reading this article or issue you must be a paid subscriber.
Sign in
